Cargando…
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus
BACKGROUND: The effectiveness of neoadjuvant treatment (NT) prior to resection of squamous cell carcinoma of the esophagus (SCCE) in terms of prolonged survival has not been proven by randomized trials. Facing considerable financial expenses and with concerns regarding the consumption of the patient...
Autores principales: | Heise, Joachim W, Heep, Hansjörg, Frieling, Thomas, Sarbia, Mario, Hartmann, Karl A, Röher, Hans-Dietrich |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC61000/ https://www.ncbi.nlm.nih.gov/pubmed/11737874 http://dx.doi.org/10.1186/1471-2407-1-20 |
Ejemplares similares
-
Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2019) -
Expression of EpCam and Villin in Barrett’s Esophagus and in Gastric Cardia
por: Anders, Mario, et al.
Publicado: (2008) -
MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2018) -
A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus
por: Zhao, Yunpeng, et al.
Publicado: (2021) -
Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)